

GLAXOSMITHKLINE PLC
Form 6-K
September 13, 2012

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending September 2012

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

--

Issued: Thursday 13 September 2012, London UK - LSE Announcement

GSK to acquire five million shares in Response Genetics for US\$1.10 per share in cash

GlaxoSmithKline plc (LSE: GSK) today announces that it has acquired five million newly issued shares of Response Genetics, Inc. (RGI) (NASDAQ: RGDY) common stock at a purchase price of US\$1.10 per share in cash. As a result, GSK now owns approximately 15.2% of the expanded share capital of RGI.

This transaction builds on the relationship GSK and RGI have been building over the years in the diagnostics field of oncology and vaccines. RGI performs companion diagnostic tests and other related activities for GSK's immunotherapies and oncology pipeline candidates.

V A Whyte
Company Secretary
13 September 2012

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com

GlaxoSmithKline

Enquiries:

| | | |
|--|-----------------------|------------------|
| UK Media enquiries: David Mawdsley | +44 (0) 20 8047 5502 | (London) |
| Stephen Rea | +44 (0) 20 8047 5502 | (London) |
| Sarah Spencer | +44 (0) 20 8047 5502 | (London) |
| David Daley | +44 (0) 20 8047 5502 | (London) |
| US Media enquiries: Kevin Colgan | +1 919 483 2933 | (North Carolina) |
| Melinda Stubbee | +1 919 483 2510 | (North Carolina) |
| Sarah Alspach | +1 202 715 1048 | (Washington, DC) |
| Jennifer Armstrong | +1 215 751 5664 | (Philadelphia) |
| Analyst/Investor enquiries: Sally Ferguson | +44 (0) 20 8047 5543 | (London) |
| Tom Curry | + 1 215 751 5419 | (Philadelphia) |
| Gary Davies | + 44 (0) 20 8047 5503 | (London) |
| James Dodwell | + 44 (0) 20 8047 2406 | (London) |

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Jeff McLaughlin + 1 215 751 7002 (Philadelphia)
Ziba Shamsi + 44 (0) 20 8047 (London)
3289

Cautionary statement regarding forward-looking statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk factors' in the 'Financial review & risk' section in the company's Annual Report 2011 included as exhibit 15.2 to the company's Annual Report on Form 20-F for 2011.

Registered in England & Wales:
No. 3888792

Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: September 13, 2012

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc